Checkmate 238: Nivolumab bests ipilimumab for resectable stage III or IV melanomaSeptember 11, 2017Melanoma
Adverse effects of PD-1/PD-L1 inhibitors varied by tumor type in systematic reviewAugust 28, 2017Melanoma
